A man with brown hair wearing a grey blazer and blue dress shirt stands in front of an MRI

Andrew Loblaw

MD, FRCPC, M.Sc.
Scientist
andrew.loblaw@sunnybrook.ca
Sunnybrook Health Sciences Centre
Phone: 416-480-4806
Fax: 416-480-6002

Research Assistant:

Barb Zurowski
Phone: 416-480-4806
Email: barb.zurowski@sunnybrook.ca

Dr Andrew Loblaw is a Radiation Oncologist, Clinician Scientist, Site Group Co-Lead for Genitourinary Oncology and Professor in the Department of Radiation Oncology at Sunnybrook Health Sciences Centre. Dr Loblaw’s clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system.

He received a Bachelor of Science in Physics from the University of British Columbia and his Doctor of Medicine from Queen’s University.  He completed his specialty training in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from the Royal College’s Clinician Investigator Program all at the University of Toronto.

Dr Loblaw’s clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system. He has a particularly interest in the design and conduct of clinical trials, the generation and dissemination of evidence-based guidelines and in image-guided radiotherapy.

Dr Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Senior Scientist at the Sunnybrook Research Institute. A Fellow of the American Society of Clinical Oncology (FASCO), he was previous Co-Chair of the ASCO’s Genitourinary Advisory Group and remains Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care. He has authored over 325 peer-reviewed papers and has been awarded grant funding of over Cdn$52M.  

Education

  • B.Sc., 1991, physics, University of British Columbia
  • MD, 1995, Queen’s University
  • FRCPC, 2000, radiation oncology, University of Toronto
  • M.Sc., 2002, clinical epidemiology, U of T
  • FRCPC, 2002, clinician investigator program, U of T

Appointments and Affiliations

  • Scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
  • Clinician scientist, Ontario Association of Radiation Oncology
  • Professor, department of radiation oncology, U of T
  • Professor, Institute of Health Policy, Management and Evaluation, U of T
  • Co-chair, genitourinary cancer disease site group, Cancer Care Ontario
  • Co-chair, genitourinary guidelines advisory group, American Society of Clinical Oncology

Research Foci

  • Design and conduct of clinical trials to improve the health care system and outcomes for men with prostate cancer
  • Development of clinical practice guidelines

Publications

Affiliated Labs & Programs

Selected Publications

  1. van As N, Tree A, Patel J, Ostler P, Van Der Voet H, Loblaw DA, Chu W, Ford D, Tolan S, Jain S, Armstrong JG, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Manning G, Brown S, Griffin C, Hall E. 5-year outcomes from PACE B: An International Phase III Randomised Controlled Trial comparing Stereotactic Body Radiotherapy (SBRT) vs Conventionally Fractionated or Moderately Hypo fractionated External Beam Radiotherapy for Localised Prostate Cancer. NEJM Oct 2024; 391:1413-25.

  2. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W…. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lanc Oncol Nov 2019; 20(11):1531-1543.

  3. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients with Prostate Cancer. J Clin Oncol 2015; 33(3):272-277.

  4. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28(1):126-131.

  5. Loblaw DA, Virgo KS, Nam R, Somerfield M, Ben-Josef E, Mendelson DS, Middleton R, Porterfield H, Sharp SA, Talcott J, Taplin ME, Vogelzang NJ, Wade JL, Bennett CL, Scher HI. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer -- 2007 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2007; 25(12):1596-1605.

In the News